Interferon-β (IFN-β) 1a for subcutaneous injection (sc) (Rebif®) was one of the first disease-modifying therapies (DMTs) approved for multiple sclerosis (MS).

Three decades of research and clinical experience have provided a wealth of data on the long-term safety, efficacy, and real-world effectiveness of IFN-β.

Through the evolving clinical landscape of MS treatment, IFN-β-1a sc has remained a mainstay of MS treatment and research.

IFN-β-1a sc continues to play a role in research into MS pathophysiology and treatment, as an active comparator and as a stable background therapy in clinical trials of other treatments.